[Clinical significance of primary and secondary prevention trials with lipid-lowering therapy against coronary heart disease].
Sakai
N
N
Department of Molecular Science and Internal Medicine, Graduate School of Medicine, Osaka University.
Yamashita
S
S
D000367:Age Factors; D000368:Aged; D001161:Arteriosclerosis / Q000209:etiology / Q000517:prevention & control; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications / Q000628:therapy*; D008019:Life Style; D008297:Male; D008875:Middle Aged; D012737:Sex Factors
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors